Steamhaus picks SignalFx to drive observability in client portfolio
Category: #tech  By Mateen Dalal  Date: 2019-08-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Steamhaus picks SignalFx to drive observability in client portfolio
  • Infrastructure Monitoring of SignalFx would offer analytics-driven alerting and real-time visibility for modern flexible cloud-native environment of Steamhaus.
  • SignalFx is the lone infrastructure monitoring solution which can identify and alert engineering teams on meaningful conditions in seconds.

SignalFx, a San Mateo based leader in SaaS-based analytics and monitoring platform, reportedly announced a collaboration with Steamhaus, a DevOps and cloud consultancy based in the UK, to help the DevOps company address monitoring needs in its client portfolio.

SignalFx will enable Steamhaus to help its clients in expediting their adoption of cutting-edge technologies which include serverless computing, Kubernetes, containers and microservices.

Technical Director at Steamhaus, Rob Greenwood stated that the company is committed in adding value to its consumers and supporting them to develop their business further by investing in continuous improvement, expertise and innovation.

Rob added that collaboration with SignalFx is the best instance of this investment, the company has now added top-of-the-line, enterprise-class cloud monitoring to the company’s 24/7 managed service.

Steamhaus is headquartered in Manchester, England and it specializes in DevOps, cloud, Amazon Web Services architecture, security and scalability. After a considerable evaluation, Steamhaus selected SignalFx to standardize its user base on the SignalFx Infrastructure Monitoring.

With SignalFlowTM, a patented streaming analytics technology, the SignalFx Infrastructure Monitoring offers analytics-driven alerting and real-time visibility for modern flexible cloud-native environments. It is the lone infrastructure monitoring solution which can identify and alert enterprises on meaningful conditions in seconds, enabling teams to remediate issues automatically before customers get affected by it.

COO at SignalFx, Mark Cranney stated that to provide the best experience for clients and rise above the competition, it is important for today’s companies to implement leading-edge technologies such as containers and microservices. Mark also stated that with SignalFx’s centralized observability, Steamhaus provides its clients the ability and confidence for doing just that. SignalFx is thrilled to collaborate with one of the technically strong and well-respected cloud-managed service providers of UK.

Source credit: https://www.signalfx.com/press/steamhaus-selects-signalfx-to-enable-observability-across-its-client-portfolio/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Lineage Cell Therapeutics’ Renevia bags CE Mark Approval for EU market
Lineage Cell Therapeutics’ Renevia bags CE Mark Approval for EU market
By Mateen Dalal

Aesthetic medicine is increasingly being used for the treatment of physical impairments such as skin discoloration, excessive fat, scars, skin laxity, wrinkles, cellulite, and liver spots. Customer are seen demanding for resurfacing and non-invasive ...

Cipla and PULM dose first patient with Pulmazole in Phase 2 ABPA trial
Cipla and PULM dose first patient with Pulmazole in Phase 2 ABPA trial
By Mateen Dalal

There is a substantial rise in the number of people affected with pulmonary diseases like asthma. Various pharmaceutical companies in the world are combining their capabilities to find treatments for serious pulmonary diseases to address the needs of...

AC Immune gets milestone payment to initiate Phase 2 trial of PI-2620
AC Immune gets milestone payment to initiate Phase 2 trial of PI-2620
By Mateen Dalal

As cases of neurodegenerative diseases like Alzheimer’s and Parkinson’s are on a rise, biopharmaceutical firms are actively engaging in developing new clinical drugs. Companies are also gaining increased funding from partners to further t...